Karin van der Tuin1, Leanne de Kock2, Eveline J Kamping3, Sabine E Hannema4, Marie-Jose M Pouwels5, Marek Niedziela6, Tom van Wezel7, Frederik J Hes1, Marjolijn C Jongmans3,8,9, William D Foulkes2, Hans Morreau7. 1. Department of Clinical Genetics, Leiden University Medical Centre, Leiden, Netherlands. 2. Department of Human Genetics, McGill University, Montreal, Quebec, Canada. 3. Department of Clinical Genetics, Radboud University Medical Centre, Nijmegen, Netherlands. 4. Department of Pediatrics, Leiden University Medical Centre, Leiden, Netherlands. 5. Department of Internal Medicine, Division of Endocrinology, Medical Spectrum Twente, Enschede, Netherlands. 6. Department of Pediatric Endocrinology and Rheumatology, Karol Jonscher's Clinical Hospital, Poznan University of Medical Sciences, Poznan, Poland. 7. Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands. 8. Department of Medical Genetics, Utrecht University Medical Center, Utrecht, Netherlands. 9. Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.
Abstract
Context: DICER1 syndrome is a rare autosomal-dominantly inherited disorder that predisposes to a variety of cancerous and noncancerous tumors of mostly pediatric and adolescent onset, including differentiated thyroid carcinoma (DTC). DTC has been hypothesized to arise secondarily to the increased prevalence of thyroid hyperplastic nodules in syndromic patients. Objective: To determine somatic alterations in DICER1-associated DTC and to study patient outcomes. Design: Retrospective series. Setting: Tertiary referral centers. Patients: Ten patients with germline pathogenic DICER1 variants and early-onset DTC. Methods: Somatic DICER1 mutation analysis, extensive somatic DNA variant and gene fusion analyses were performed on all tumors. Results: Median age at DTC diagnosis was 13.5 years and there was no recurrent or metastatic disease (median follow-up, 8 years). All thyroid specimens showed diffuse nodular hyperplasia with at least one focus suspicious of DTC but without infiltrative growth, extrathyroidal extension, vascular invasion, or lymph node metastasis. Most of the individual nodules (benign and malignant) sampled from the 10 tumors harbored distinct DICER1 RNase IIIb hotspot mutations, indicating a polyclonal composition of each tumor. Furthermore, nine of 10 DICER1-related DTCs lacked well-known oncogenic driver DNA variants and gene rearrangements. Conclusion: On the basis of our clinical, histological, and molecular data, we consider that most DICER1-related DTCs form a low-risk subgroup. These tumors may arise within one of multiple benign monoclonal nodules; thus, hemi-thyroidectomy or, more likely, total thyroidectomy may often be required. However, radioiodine treatment may be unnecessary given the patients' ages and the tumors' low propensity for metastases.
Context:DICER1 syndrome is a rare autosomal-dominantly inherited disorder that predisposes to a variety of cancerous and noncancerous tumors of mostly pediatric and adolescent onset, including differentiated thyroid carcinoma (DTC). DTC has been hypothesized to arise secondarily to the increased prevalence of thyroid hyperplastic nodules in syndromicpatients. Objective: To determine somatic alterations in DICER1-associated DTC and to study patient outcomes. Design: Retrospective series. Setting: Tertiary referral centers. Patients: Ten patients with germline pathogenic DICER1 variants and early-onset DTC. Methods: Somatic DICER1 mutation analysis, extensive somatic DNA variant and gene fusion analyses were performed on all tumors. Results: Median age at DTC diagnosis was 13.5 years and there was no recurrent or metastatic disease (median follow-up, 8 years). All thyroid specimens showed diffuse nodular hyperplasia with at least one focus suspicious of DTC but without infiltrative growth, extrathyroidal extension, vascular invasion, or lymph node metastasis. Most of the individual nodules (benign and malignant) sampled from the 10 tumors harbored distinct DICER1 RNase IIIb hotspot mutations, indicating a polyclonal composition of each tumor. Furthermore, nine of 10 DICER1-related DTCs lacked well-known oncogenic driver DNA variants and gene rearrangements. Conclusion: On the basis of our clinical, histological, and molecular data, we consider that most DICER1-related DTCs form a low-risk subgroup. These tumors may arise within one of multiple benign monoclonal nodules; thus, hemi-thyroidectomy or, more likely, total thyroidectomy may often be required. However, radioiodine treatment may be unnecessary given the patients' ages and the tumors' low propensity for metastases.
Authors: Rebecca D Chernock; Barbara Rivera; Nicla Borrelli; D Ashley Hill; Somayyeh Fahiminiya; Tasha Shah; Anne-Sophie Chong; Barina Aqil; Mitra Mehrad; Thomas J Giordano; Rachel Sheridan; Meilan M Rutter; Louis P Dehner; William D Foulkes; Yuri E Nikiforov Journal: Mod Pathol Date: 2020-01-14 Impact factor: 7.842
Authors: Mays Altaraihi; Thomas van Overeem Hansen; Eric Santoni-Rugiu; Maria Rossing; Åse Krogh Rasmussen; Anne-Marie Gerdes; Karin Wadt Journal: Front Endocrinol (Lausanne) Date: 2021-09-06 Impact factor: 5.555
Authors: Mehtap Derya Aydemirli; Marieke Snel; Tom van Wezel; Dina Ruano; Christianne M H Obbink; Wilbert B van den Hout; Abbey Schepers; Hans Morreau Journal: Endocrinol Diabetes Metab Date: 2021-09-02
Authors: Jette J Bakhuizen; Helen Hanson; Karin van der Tuin; Fiona Lalloo; Marc Tischkowitz; Karin Wadt; Marjolijn C J Jongmans Journal: Fam Cancer Date: 2021-06-25 Impact factor: 2.446